Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Teva Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: flatsville who wrote (297)	7/27/2001 11:26:13 AM
From: Dorine Essey	Respond to of 340

Hi, You sound like me. My husband and I went away all the time. Our life was a vacation. I lost him this past July 4.2001. I sure hope you own TEVA.I only have 400 shares. Wish I had more. They are due for a split. Dorine Have a great time .

To: flatsville who wrote (297)	7/29/2001 11:27:15 PM
From: Dorine Essey	Respond to of 340

Sun: Looking beyond the results Shlomo Greenberg 29.07.2001 17:21 . What we’ve been saying is not, of course, applicable to the pharmaceuticals and generic industry. There’s no lack of demand in this sector. Nor are there any surplus inventories. In this sector, it’s business as usual. Taro Pharmaceutical Industries (Nasdaq: TARO) is still going up. The company is planning to take advantage of the share price to raise $250-300 million. If the issue goes well, and there’s no reason to think it won't, the company’s management deserves a pat on the back. Not because of the share, although this, too, is important, but because of what actually happened in the company in the past two years. Taro will hold an issue at a high company value, raising a sum that will allow the company to ease its way into a higher level. We’ve nearly forgotten to tell you that the share rose another 5.5% to $47.15, the new price after the split. Teva (Nasdaq: TEVA) has also done well recently, climbing 21% since the beginning of the month to $73.05 on Friday. Look what happened over the past year. Would anyone use the phrase “Teva did well, also” after talking about Taro a year ago? Would anyone have mentioned the two in the same breath a year ago? Taro is still a very far cry from Teva, but what happened shows that when it comes to Wall Street and to the drug industry, anything is possible

To: flatsville who wrote (297)	8/2/2001 4:23:18 PM
From: Dorine Essey	Respond to of 340

Check my recent post. I meant to send it to you. Dorine

To: flatsville who wrote (297)	2/12/2002 9:05:53 AM
From: Dorine Essey	Read Replies (1) \| Respond to of 340

Nessuah Zannex: Further Teva acquisition in pipeline Globes' corespondent 12.02.2002 11:56 In a report issued ahead of the publication of Teva's (Nasdaq: TEVA) 2001 results on Thursday, Nessuah Zannex says that it expects the completion of the purchase of Bayer Classic within a few weeks, “with a further significant acquisition in the pipeline.” Nessuah Zannex reiterates its “Buy” recommendation for the share, with a twelve month price target of $79. Teva closed at $59.66 on Wall Street yesterday. The report predicts that Teva will show revenue of $2,055.6 million for 2001, 17.5% more than in 2000. Nessuah Zannex’s profit projection is $284.6 million, 88% above the 2000 figure. This gives an EPS of $2.07 (fully diluted), above the market consensus of $2.05, Nessuah Zannex says.